Top Page
Microbix Biosystms
(TSX:MBX)
Microbix Biosystms (MBX) vs. iShares MSCI Canada ETF (EWC)
Microbix Biosystms Business Overview & Revenue Model
Microbix Biosystms Earnings Call Summary
Microbix Biosystms Financial Statement Overview
| Breakdown | |||||
| TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 23.03M | 25.39M | 16.51M | 19.08M | 18.59M | 10.52M | Gross Profit |
| 12.92M | 15.39M | 7.48M | 11.12M | 11.04M | 4.66M | EBIT |
| 1.59M | 3.91M | -2.74M | 2.69M | 4.84M | -524.60K | EBITDA |
| 4.51M | 6.21M | 1.96M | 3.73M | 5.66M | -2.91M | Net Income Common Stockholders |
| 1.92M | 3.52M | -39.48K | 1.79M | 1.63M | -6.23M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 13.05M | 12.96M | 11.61M | 13.49M | 9.99M | 92.66K | Total Assets |
| 39.30M | 38.10M | 35.65M | 33.15M | 28.83M | 15.60M | Total Debt |
| 6.44M | 6.40M | 6.65M | 5.82M | 7.74M | 6.17M | Net Debt |
| -6.61M | -6.57M | -4.96M | -7.66M | -2.25M | 6.08M | Total Liabilities |
| 10.40M | 9.80M | 11.03M | 8.21M | 10.27M | 8.98M | Stockholders Equity |
| 28.90M | 28.30M | 24.62M | 24.94M | 18.56M | 6.62M |
| Cash Flow | Free Cash Flow | ||||
| 1.73M | 2.44M | -2.11M | 1.44M | 804.20K | -805.34K | Operating Cash Flow |
| 3.80M | 4.35M | -1.09M | 3.47M | 2.11M | 8.57K | Investing Cash Flow |
| -2.07M | -1.91M | -1.02M | -2.03M | -622.34K | -813.91K | Financing Cash Flow |
| -1.46M | -1.08M | 229.21K | 2.06M | 8.41M | 802.43K |
Microbix Biosystms Technical Analysis
Microbix Biosystms Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | C$64.43M | 16.70 | 14.51% | ― | 28.97% | ― | |
68 Neutral | C$42.24M | 25.86 | 5.32% | ― | -4.67% | -60.94% | |
54 Neutral | $5.38B | 3.40 | -45.06% | 3.28% | 16.75% | -0.02% | |
46 Neutral | C$60.66M | ― | ― | -32.14% | -52.38% | ||
43 Neutral | $50.63M | ― | -211.24% | ― | ― | 0.10% | |
33 Underperform | C$54.20M | ― | 248.46% | ― | ― | 32.71% | |
33 Underperform | C$68.96M | ― | 685.26% | ― | ― | -50.29% |
Microbix Biosystms Corporate Events
Microbix Biosystems reported its Q2 fiscal 2025 results, showing a revenue of $5.3 million, a slight decrease from the previous year, but with improved gross margins. The company experienced growth in antigen sales, offset by a decline in QAPs due to delays with a major customer. Despite increased operating expenses, Microbix achieved a positive net income and improved financial strength, with strong cash reserves and liquidity. However, the outlook for the second half of fiscal 2025 is cautious due to reduced sales in China, impacting the company’s future growth prospects.
The most recent analyst rating on (TSE:MBX) stock is a Buy with a C$0.80 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.
Microbix Biosystems Inc., in collaboration with Aurevia Oy, has launched a pilot external quality assessment (EQA) program aimed at enhancing the proficiency of clinical laboratories in diagnosing bacterial vaginosis (BV) using molecular diagnostic methods. This initiative, which involves the use of Microbix’s QAPs to simulate clinical specimens, is expected to improve diagnostic accuracy and treatment planning for BV and other vaginal infections. The program’s success could lead to its inclusion in Aurevia’s Labquality EQAS portfolio, thereby strengthening Microbix’s position as a key partner in the diagnostics industry.
The most recent analyst rating on (TSE:MBX) stock is a Buy with a C$0.80 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.
Microbix Biosystems Inc. has announced the release of its second quarter fiscal 2025 financial results, scheduled for May 15, 2025. The company will host a webinar to discuss these results, featuring its CEO, CFO, and COO. This event reflects Microbix’s ongoing commitment to transparency and engagement with investors and stakeholders, potentially impacting its market positioning and investor relations.
Microbix Biosystems Inc. announced that its partner, Sequel Pharma, has signed an agreement with a contract development and manufacturing organization (CDMO) to produce Kinlytic® urokinase, a drug for dissolving blood clots. This agreement aims to resume production for the U.S. market, initially targeting the catheter clearance segment valued at $400 million. The collaboration is expected to enhance Microbix’s market presence and operational capabilities, with future updates anticipated as the project progresses.
Microbix Biosystems Inc. announced its participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference, which will be held at the Metro Toronto Convention Centre. This event provides Microbix with a platform to connect with Canadian, U.S., and international investors, potentially enhancing its market presence and stakeholder engagement in the healthcare and life sciences sector.
Microbix Biosystems Inc. announced its participation in the ESCMID Global 2025 conference, where it will showcase its innovative Quality Assessment Products (QAPs) designed to ensure the accuracy of diagnostic tests. A customer and collaborator, Labquality EQAS by Aurevia, will present results from a pilot External Quality Assessment program for Norovirus antigen detection, supported by Microbix’s QAPs. This initiative highlights Microbix’s capability to create effective controls for challenging antigen materials, enhancing its industry positioning and demonstrating its commitment to quality management in diagnostics.
Microbix Biosystems Inc. announced that its products remain exempt from new U.S. tariffs, providing a competitive edge over other international exporters facing tariffs. The company is also exploring Canadian procurement opportunities amid potential reciprocal tariffs on U.S. goods. While the outlook for its QAPs business remains strong, sales of test-ingredients, particularly antigens, have been affected by reduced demand in China. Despite these challenges, Microbix continues to expand its capabilities and remains financially robust, with significant cash reserves and ongoing strategic initiatives in diagnostics and synthetic biology.
Microbix Biosystems Inc. announced the results of its Annual and Special Meeting of Shareholders, where 42.83% of the issued and outstanding shares were represented, and all resolutions were approved, including the re-election of board members and the re-appointment of auditors. This positive outcome reflects shareholder confidence and supports the company’s ongoing operations and strategic initiatives in the life sciences sector.
Microbix Biosystems Inc. has optimized its capital structure by repaying a C$ 1.2 million mortgage and expanding its line of credit from C$ 2.0 million to C$ 4.0 million. These financial moves are expected to reduce interest expenses and provide greater strategic flexibility, allowing the company to reinvest in growth and adapt to market changes. With these changes, Microbix aims to maintain financial strength, support operations, and ensure resilience against economic uncertainties.
Microbix Biosystems Inc. has signed a Memorandum of Understanding with the Australian Centre for the Prevention of Cervical Cancer (ACPCC) to supply its PROCEEDxFLOQ brand Quality Assessment Products (QAPs) to support the accuracy of HPV testing in the Indo-Pacific region. This collaboration is part of the EPICC program, which aims to eliminate cervical cancer in the region by improving the prevention, diagnosis, and treatment of the disease. The initiative is supported by the Australian Government and philanthropic partners and seeks to extend its proven model to additional countries, enhancing access to accurate HPV testing and reducing the human toll of cervical cancer.